ARMO BioSciences's Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival
It is particularly promising to see these high, durable responses in advanced NSCLC patients with low as well as high PD-L1 expression and in intermediate to poor risk advanced RCC patients who have received 2 or more prior therapies."09/11/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 10, 2017 Category: Urology & Nephrology Source Type: news
Translocation Renal Cell Carcinoma: An Update
Microphthalmia-associated transcription (MiT) family translocation renal cell carcinoma (tRCC) comprises Xp11 tRCC and t(6;11) RCC.08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news
Advice For Newly Diagnosed Patients From Mike Lawing
Michael B. Lawing from Rutherford County, NC is involved in advocacy for cancer patients at the local, National and International levels. He serves as a Member of the Board of Directors of the Kidney Cancer Association, the world ’s largest non-profit dealing exclusively with Kidney Cancer with over 90,000 members in 102 countries.08/26/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news
AVEO Pharma stock rises 6% after cancer drug gets approved
The drug, Fotivda, was approved for adults with advanced renal cell carcinoma -- the most common type of kidney cancer08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news
Exelixis Submits sNDA for Kidney Cancer Drug
The sNDA submission was based on positive results from phase II trial, CABOSUN, in patients with previously untreated advanced RCC with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).08/20/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 19, 2017 Category: Urology & Nephrology Source Type: news
California kidney cancer shows declining incidence
The research study, published online in the peer-reviewed journal Kidney Cancer, is important because it is the first report to demonstrate that the rising rate of kidney cancer seen in the U.S. over the past two decades may have ended.08/19/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 19, 2017 Category: Urology & Nephrology Source Type: news
Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal
...use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.08/16/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 16, 2017 Category: Urology & Nephrology Source Type: news
Advice For Newly Diagnosed Patients From Our Director Mike Lawing
Michael B. Lawing from Rutherford County, NC is involved in advocacy for cancer patients at the local, National and International levels. He serves as a Member of the Board of Directors of the Kidney Cancer Association, the world ’s largest non-profit dealing exclusively with Kidney Cancer with over 90,000 members in 102 countries.08/26/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 15, 2017 Category: Urology & Nephrology Source Type: news
Patent for Enhancing Immunotherapy in Cancer Treatment Granted
This patent provides intellectual property protection for the ongoing human trial that evaluates the effect of the combination of GR-MD-02 with approved cancer immunotherapy drugs08/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 15, 2017 Category: Urology & Nephrology Source Type: news
NICE knocks back advanced kidney cancer drug duo
While the guidance is only in its draft stage, the decision could mean that Eisai ’s Kisplyx (lenvatinib) and Eusa Pharma’s Fotivda (tivozanib) are withheld from NHS patients in England and Wales.08/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 15, 2017 Category: Urology & Nephrology Source Type: news
Dr. Choueiri Discusses Novel RCC Drug Combos
In an interview with OncLive during ASCO, the study ’s lead author, Toni Choueiri, MD, senior physician and director of the Kidney Cancer Center at Dana-Farber Cancer Institute, reflected on the avelumab/axitinib results and other emerging combos in RCC.08/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 5, 2017 Category: Urology & Nephrology Source Type: news
New Journal, Kidney Cancer, Launched With Expert Editorial Board
Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the kidney.07/21/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 21, 2017 Category: Urology & Nephrology Source Type: news
Exelixis Announces Settlement of Dispute with Genentech Regarding Companies ’ Collaboration
Effective July 1, 2017, as part of the settlement the companies entered into an amendment (the “Amendment”) to the existing Collaboration Agreement, dated December 22, 2006, to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016, and aligns both companies’ interes ts in advancing cobimetinib as a promising therapy for patients with multiple forms of cancer.07/21/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 21, 2017 Category: Urology & Nephrology Source Type: news
OncLive ® Presents State of the Science Summit™ on Genitourinary Malignancies
This educational event will discuss some of the most pressing issues faced by oncologists and other medical experts when dealing with genitourinary malignancies. The summit will discuss critical topics such as bone targeting, treatment of castration-resistant metastatic prostate cancer, kidney cancer and new clinical trials.07/21/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 21, 2017 Category: Urology & Nephrology Source Type: news
